Tolremo therapeutics is a biotech company focused on transforming cancer treatment by targeting transcriptional resistance pathways that lead to drug resistance
Tolremo therapeutics is a biotech company focused on transforming cancer treatment by targeting transcriptional resistance pathways that lead to drug resistance. Their mission is to develop therapies that prevent cancer cells from evading targeted treatments, with a lead compound TT125-802, a small molecule inhibitor of CBP/p300 bromodomain, currently in clinical trials.